Anthony M. (Tony) Lowman has served as the Dean of the College of Engineering at Rowan University since January of 2013. Previously, he served as Vice Provost for Research and Business Development at Temple University. His areas of responsibility included development of sponsored programs and partnerships between the University, Industry and Government Agencies, aimed at developing technologies and solutions to societal issues with. Prior to his Temple appointment, he served as Associate Dean for Research and Graduate Studies and Associate Dean for Undergraduate Affairs in the College of Engineering and Professor of Chemical Engineering at Drexel. He received his education in chemical engineering at the University of Virginia (B.S., 1993) and at Purdue University (Ph.D., 1997).
His research contributions have been in the area of polymers for biomedical applications. He is known for his work on the preparation, characterization and evaluation of the behavior of compatible, crosslinked polymers known as hydrogels, which have been used as biocompatible materials and in controlled release devices, especially in controlled delivery of drugs, peptides and proteins, and the development of novel biomaterials. Based on his innovative work, in September of 2003 he was honored as one of the top 100 Scientific Innovators in the world under the age of 35 as named by the MIT-Technology Review Magazine. His work has received funding from the Depts of Defense, Energy and Commerce, NIH, NSF, the Whitaker Foundation and private industry. Tony is a Fellow of the American Institute of Medical and Biological Engineers and the National Academy of Inventors.
In addition to his main academic appointment, Tony has been active in international collaboration with major research centers around the world with appointments and joint programs developed with Hoshi University of Tokyo, University of Parma, Italy and Politechnico de Milano in Milan, Italy. Additionally, in 2002 Tony co-founded Gelifex, Inc., a company pursuing non-invasive methods for using hydrogels for repair of the nucleus pulposus of the intervertebral disc. Gelifex was acquired by Synthes, now part of Johnson and Johnson, in 2004.